Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in quality of life in patients with atrial fibrillation and central sleep apnea treated with transvenous phrenic nerve stimulation.

Sleep medicine·2026
Same author

Phrenic nerve stimulation for treatment of central sleep apnea.

Frontiers in sleep·2025
Same author

Central Sleep Apnea in Heart Failure: What Now?

Archivos de bronconeumologia·2025
Same author

Classifying hypopneas as obstructive or central can enhance transvenous phrenic nerve stimulation therapy patient selection and outcomes.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2025
Same author

Idiopathic central sleep apnea: the past, the present, and the future.

Sleep·2025
Same author

Nocturnal Oxygen Therapy for Central Sleep Apnea in Patients with Heart Failure: A Multisite, Double-Blind, Sham-controlled Randomized Clinical Trial (LOFT-HF).

Annals of the American Thoracic Society·2025
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Related Experiment Video

Updated: Jul 1, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Sleep dysfunction in heart failure.

Shahrokh Javaheri1

  • 1Shahrokh Javaheri, MD Sleepcare Diagnostics, 4780 Socialville-Fosters Road, Cincinnati, OH 45040, USA. Javaheri@snorenomore.com.

Current Treatment Options in Neurology
|September 11, 2008
PubMed
Summary
This summary is machine-generated.

Sleep disorders like sleep apnea are common in heart failure patients and linked to higher mortality. Effective CPAP treatment improves survival, with alternative therapies available for non-responders.

More Related Videos

Quantifying Infra-slow Dynamics of Spectral Power and Heart Rate in Sleeping Mice
10:56

Quantifying Infra-slow Dynamics of Spectral Power and Heart Rate in Sleeping Mice

Published on: August 2, 2017

Related Experiment Videos

Last Updated: Jul 1, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Quantifying Infra-slow Dynamics of Spectral Power and Heart Rate in Sleeping Mice
10:56

Quantifying Infra-slow Dynamics of Spectral Power and Heart Rate in Sleeping Mice

Published on: August 2, 2017

Area of Science:

  • Cardiology
  • Sleep Medicine
  • Pulmonology

Background:

  • Chronic congestive heart failure (CHF) is a widespread, progressive condition with significant morbidity, mortality, and economic burden.
  • Sleep disorders are highly prevalent in CHF patients, affecting both systolic and diastolic dysfunction, particularly in older individuals.
  • Existing research primarily focuses on systolic heart failure, with less systematic study on diastolic dysfunction and its associated sleep issues.

Purpose of the Study:

  • To review the types and impact of sleep disorders in patients with chronic congestive heart failure.
  • To evaluate current and alternative treatment strategies for various sleep disorders in heart failure.
  • To highlight the association between sleep disorders, treatment efficacy, and patient survival in heart failure.

Main Methods:

  • Systematic review of prospective studies on sleep disorders in heart failure patients.
  • Analysis of treatment outcomes for obstructive sleep apnea (OSA) and central sleep apnea (CSA) using positive airway pressure (PAP) devices.
  • Evaluation of therapeutic options for periodic limb movements (PLM) and insomnia in the context of heart failure.

Main Results:

  • Obstructive sleep apnea and central sleep apnea are common in CHF and linked to increased mortality.
  • Continuous positive airway pressure (CPAP) improves survival in CHF patients with both OSA and CSA.
  • Alternative therapies like pressure support servo-ventilators and nocturnal oxygen are effective for CPAP-refractory CSA; pramipexole/ropinirole for RLS/PLM; ramelteon for insomnia.

Conclusions:

  • Sleep disorders significantly impact CHF prognosis and require effective management.
  • CPAP therapy is a cornerstone treatment for sleep apnea in heart failure, improving survival.
  • A multi-faceted approach addressing various sleep disturbances is crucial for optimizing outcomes in patients with chronic congestive heart failure.